comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 14:20:05 - browse：636

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Everything to know for the next Powerball drawing as jackpot hits $1 billion

WSS

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Results on Novartis prostate cancer therapy could expand its use

Readout LOUD podcast: Live from the 2023 STAT Summit

J&J lung cancer data amount to new salvo against AstraZeneca

Smaller biotechs seek to piggyback on weight loss drug boom

Wikipedia

comprehensive

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Questions loom on AstraZeneca cancer drug as safety concerns ebb

How to save PrEP access — and even expand it

Global childhood vaccinations edge closer to pre

Cancer drug shortages should be causing more outrage

STAT Summit: How researchers deal with rejection

The high cost of giving birth even with insurance

Does aspartame cause cancer? What new WHO guidance says

After affirmative action ruling, medical educators look to 'holistic review'

Global childhood vaccinations edge closer to pre

hotspot

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Readout: Friday, Oct. 20 biotech updates

STAT Readout Newsletter: Biotech news today

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Federal judge rules Oregon’s tough new gun law is constitutional

FDA clears Verve to begin U.S. study of gene

focus

focus

leisure time

explore